The CAV1 Knockout A-549 Polyclonal Cells product provides a CRISPR/Cas9-edited polyclonal population of A-549 human lung adenocarcinoma cells with targeted disruption of the CAV1 gene. This heterogeneous knockout pool is generated without single-cell cloning, representing a mixture of genomes carrying diverse CAV1 mutations. It serves as a loss-of-function tool for studying caveolin-1 biology in a lung cancer context.
The A-549 cell line is an extensively characterized model of human lung adenocarcinoma, originally derived from a 58-year-old Caucasian male. These epithelial cells harbor a KRAS mutation and are widely utilized in cancer research, including studies on oncogenic signaling, metastasis, and therapeutic resistance. Their robust growth and relevance to non-small cell lung carcinoma make them an ideal platform for genetic perturbation.
Caveolin-1 (CAV1) is a scaffolding protein essential for the formation of caveolae and functions as a signaling nexus. CAV1 gene expression is regulated by FOXO transcription factors, p53, STAT3, EGR-1, and TGF-??, and is influenced by insulin and oxidative stress. The CAV1 protein directly interacts with eNOS, Src family kinases, H-Ras, EGFR, integrins, and TGF-?? receptors, and it recruits these molecules to detergent-resistant membrane domains. Through these interactions, CAV1 modulates MAPK/ERK and PI3K/Akt cascades, ??-catenin stability, and endocytic trafficking, thereby coordinating cell proliferation, survival, and migration.
In A-549 cells, disruption of CAV1 is predicted to ablate caveolae and reorganize critical signaling pathways. Given the cell line??s KRAS-mutant background and dependency on EGFR and TGF-?? signaling, knockout of CAV1 may alter phosphorylation of ERK1/2 and Akt, ??-catenin-mediated transcription, and cellular responses to chemotherapeutics. This model thus enables mechanistic dissection of CAV1-dependent regulation of drug sensitivity, epithelial-mesenchymal transition, and cholesterol homeostasis in lung adenocarcinoma.
Researchers can apply this polyclonal knockout population in diverse cancer biology applications, including investigation of drug resistance mechanisms, caveolae biology, and tumor microenvironment interactions. Representative assays include western blotting and immunofluorescence to validate CAV1 disruption, proliferation and migration/invasion tests, phospho-signaling analysis (p-ERK, p-Akt), RT-qPCR for downstream targets, and co-immunoprecipitation of CAV1 interactors. Additionally, flow cytometry facilitates apoptosis and cell cycle studies. The mixed genotype also supports biomarker discovery and co-culture experiments. For additional technical information, please contact Ascent Research.
